Radiation Immunodynamics: The Immune Response to Standard Therapy in Patients with Glioblastoma
Johns Hopkins Kimmel Cancer Center in Baltimore
This study is assessing the immune system response during radiation therapy. The study involves measuring frequency of blood myeloid cells during radiotherapy/ temozolomide. The hypothesis of the study is : radiation increases immunosuppressive myeloid
Inclusion 1. Greater than or equal to 18 years old2. Newly diagnosed glioblastoma, untreated except for surgery and corticosteroids2. Selected for standard radiotherapy (5940-6000 cGy) and temozolomide (75 mg/m2/day)We will also recruit up to an additional 10 patients receiving non-standard radiation fractionation schemes for immunologic comparison.Exclusion 1. Recurrent GBM
22 patients will be recruited with pathologically confirmed new GBM. Radiation will be given for 5 days a week. Donor Blood will be collected at seven time points: ±7 days of RT simulation prior to start of RT, every 7±3 fractions throughout the duration of RT, within 7 days of the last fraction of RT and one month after RT ±7 days. . Donor blood will be processed immediately following collection of each biosample at The Bloomberg~Kimmel Institute for Cancer Immunotherapy at JHH.
03/05/2019 05:03 AM